Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones

Abstract Background The ongoing global malaria eradication campaign requires development of potent, safe, and cost-effective drugs lacking cross-resistance with existing chemotherapies. One critical step in drug development is selecting a suitable clinical candidate from late leads. The process used...

Full description

Bibliographic Details
Main Authors: Yizhe Chen, Fangyi Zhu, Jared Hammill, Gloria Holbrook, Lei Yang, Burgess Freeman, Karen L. White, David M. Shackleford, Kathleen G. O’Loughlin, Susan A. Charman, Jon C. Mirsalis, R. Kiplin Guy
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Malaria Journal
Subjects:
Online Access:https://doi.org/10.1186/s12936-021-03617-1